Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 7Endocrine 7Thoracic 2Sarcoma 1NET 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Neuroendocrine Tumors 43Carcinoma, Neuroendocrine 8Gastro-enteropancreatic neuroendocrine tumor 7Sarcoma 6Carcinoid Tumor 6Stomach Neoplasms 5Small Cell Lung Carcinoma 5Paraganglioma 5Neoplasms 5Prostatic Neoplasms 4Pheochromocytoma 4Neoplasm Metastasis 4Lung Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Carcinoma 4Thyroid Neoplasms 3Neuroblastoma 3Carcinoma, Renal Cell 3Thyroid Diseases 2Thoracic Neoplasms 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Ovarian Neoplasms 2Neuroectodermal Tumors 2Neoplasms, Germ Cell and Embryonal 2Neoplasms by Site 2Neoplasms by Histologic Type 2Meningioma 2Medulloblastoma 2

Interventions

tislelizumab 1surufatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Thyroid Carcinoma, Anaplastic × NET × Clear all
NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡